Objective To explore the impact of equine corneal fibroblast (ECF) to myofibroblast (ECM) differentiation by altering the expression of the Smad genes either individually or in combination. Specifically, we sought to examine the ECF differentiation after (a) silencing of Smad2, 3, and 4 profibrotic genes individually and (b) overexpression of antifibrotic Smad7 gene and in a combination with pro-and antifibrotic Smad genes. Methods Equine corneal fibroblast primary cultures were generated as previously described. ECFs were transfected with individual plasmids which silenced gene expression of either Smad2, 3, or 4 or in combination with a plasmid overexpressing Smad7 using Lipofectamine 2000 TM or Lipofectamine BLOCK-iT TM . Smad-transfected clones were then exposed to TGF-b1 to induce differentiation to myofibroblasts. Immunofluorescence and qRT-PCR techniques quantified levels of ECF differentiation to ECM by measuring alpha smooth muscle actin, a known marker of ECM transdifferentiation. Results Silencing of individual Smad2, 3, or 4 genes or overexpression of Smad7 showed significant inhibition of ECF transdifferentiation (73-83% reduction). Silencing of Smad2 showed the greatest inhibition of ECF transdifferentiation in (a) and was therefore utilized for the combination gene transfer testing. The combination gene transfer consisting of Smad7 overexpression and Smad2 silencing attenuated ECF differentiation significantly; however, the level was not significant compared to the overexpression of Smad7 individually. Conclusions Using gene transfer technology involving profibrotic Smad silencing, antifibrotic Smad overexpression or its combination is a novel strategy to control TGF-b1-mediated fibrosis in equine fibroblasts. Combination gene therapy was not better than single gene therapy in this study.
INTRODUCTION
Horses due to their prominent globe position, globe size, and other environmental factors are at high risk for developing corneal ulceration. 1, 2 Once ulcerated, corneal disease is often perpetuated through secondary infection of either bacterial or fungal origin. [3] [4] [5] [6] [7] Once resolved, the cornea is often left with a scar that leads to a reduction in the visual field. Corneal scar formation is a recognized problem afflicting not only horses, but in many of our domestic animal species, [8] [9] [10] [11] [12] [13] as well as people. 14 This loss of corneal transparency can result in a horse being unable to perform its duties such as racing, jumping, or trail riding and can prove to be dangerous to both itself and his/ her handler. 8 Due to the unique anatomical structure of the cornea, corneal wound repair is unlike wound repair found in the rest of the body. 15 Corneal scar formation in mammals is a complex cascade that is initiated by a break in the corneal epithelium and involves the transformation of quiescent keratinocytes to activated fibroblasts, alterations in the extracellular matrix, increased secretion of matrix metallic proteinases (MMPs), and altered gene expression most notably the Smad family of genes.
The Smad family of genes consists of the pro-fibrotic genes Smad2, 3 (receptor-activated Smads), Smad4 (common-partner Smad), and the antifibrotic or inhibitory gene Smad7. These genes become activated once corneal stroma is exposed to transforming growth factor beta 1 (TGF-b1), one of the most potent activators of fibrosis, [17] [18] [19] after a break in corneal epithelium. 15 The activation of the TGFb1-mediated fibrotic pathway is perpetuated through the Smad signaling pathway once TGF-b1 binds to a corneal keratocyte membrane's serine/threonine receptor. This in turn activates Smad2 and Smad3 to heterodimeric complexes that couple with a common mediator Smad4, and this complex then travels to the nucleus resulting in transcription of target genes which results in an alteration in extracellular matrix components. 20, 21 Smad7 competitively binds to the TGF-b receptor inhibiting TGF-b signal transduction and thereby altering the response of Smad2 and Smad3. 22 Multiple studies have been performed on this group of genes examining the fibrotic effects after altering Smad7 expression. 21, 23, 24 These studies have shown that downregulation of Smad2 and Smad3 occurs when Smad7 is artificially expressed. To the authors' knowledge, combination gene therapy in which the profibrotic arm of the Smad family was inhibited, while simultaneously upregulating the antifibrotic Smad7 has never before been examined in equine veterinary medicine. Therefore, we sought to determine the degree of fibrotic change as identified by the transformation of equine corneal fibroblasts (ECFs) to equine corneal myofibroblasts (ECMs) by both inhibiting and overexpressing different genes within the Smad family. This study aimed specifically to (a) examine the effects of Smad2, 3, and 4 gene silencing individually, Smad7 gene overexpression on ECF transdifferentiation in response to TGF-b1, and to identify the greatest potential of profibrotic Smad gene silencing on ECF differentiation, and (b) compare the level of inhibition of ECF transdifferentiation to ECM by individual vs combination gene transfer of pro-and antifibrotic Smads. It was our hypothesis that Smad gene transfer in combination would yield a greater antifibrotic effect than individual Smad gene transfer in equine corneal fibroblast in an in vitro model of corneal fibrosis.
METHODS

Generation of cell cultures
Primary cultures of ECFs and ECMs were generated as previously described. 25 Briefly, all corneal sections were harvested from healthy research horses being euthanized for reasons unrelated to this study. Prior to euthanasia, slit-lamp biomicroscopy was performed by a board-certified veterinary ophthalmologist (EAG) to ensure that all horses were free of anterior segment disease. Immediately following euthanasia, 6 mm full thickness corneal buttons were harvested aseptically and immediately transported to the laboratory for further processing. All corneal buttons were washed with modified eagle media (Life technologies, Carlsbad, CA), and the corneal epithelium and endothelium were aseptically removed by scraping with a #10 bard parker blade (Aspen Surgical, Caledonia MI). The corneal buttons were then subsectioned into four equal sized pieces and placed into a 100 9 20 mm tissue culture plate (Fisher Scientific, Pittsburg, PA), and supplemented with MEM media containing 10% fetal bovine serum, penicillin, streptomycin, fungizone, and ciprofloxacin. All culture plates were incubated at 37°C in a humidified CO 2 chamber. Once 90% confluence was achieved (2-4 weeks) of the primary ECF monolayer, all corneal stromal sections were removed, and the ECFs were then trypsinized for use in all other phases of this study. ECFs were counted prior to plating, and a volume of 7.5 9 10 4 was used. ECMs were achieved for all phases of this study by supplying ECFs with MEM media supplemented with 5 ng/ml TGF-b1. Both a negative control group (cultured ECFs not exposed to TGF-b1) and a positive control group (ECFs exposed to TGF-b1 only) were utilized as standards for all analytical testing.
Gene transfections
All RNA interference (RNAi) oligos (Table 1) were prevalidated through a previous experiment in our laboratory. 16 Furthermore, the DNA sequences of RNAi in all plasmids were verified from the PubMed gene database to ensure a complete matching with the equine genome. The RNAi oligos were cloned into pcDNA 6.2 miR RNAi commercial vector (Life technologies, Carlsbad, CA). The Lipofectamine 2000 TM BLOCK-iT TM transfection kit (Invitrogen Corporation, Carlsbad, CA) was utilized for all transfections according to manufacturer's instructions. In summary, all ECF cell cultures were 90% confluent at the time of transfection. Twenty-four hours prior to transfection, ECF cell cultures were supplemented with serum and antibiotic-free DMEM (Dulbecco's modified Eagle's medium). The desired amount of the siRNA/RNAi plasmid and 10 lL of Lipofectamine 2000 TM were combined and incubated at room temperature for 5 min, after which this combination was aliquoted to ECF cultures individually. During the transfection process and for the first 4 h Table 1 . Nucleotide sequences of validated RNAi used in study
afterward, only serum-free DMEM was utilized. After 4 h, MEM media mixed as previously stated with TGF-b1 were utilized until the termination of the experiment at 72 h. Prior to performing the transfection utilizing Smad plasmids, we validated the transfection efficiency of Lipofectamine 2000 TM using the plasmid pcDNA3.1-m-cherry. Results of our studies demonstrated transfection efficiency of Lipofectamine between 80 and 85% (Fig. 2f) .
Gene expression and quantification
Following the termination of the experiment period, RNA was extracted from cells of all groups using a RNeasy kit (Qiagen, Valencia, CA) in accordance with manufacturer's instructions and reverse transcribed to cDNA as previously reported. 9 Samples were then stored at À80°C until analyzed by real-time qPCRs (qRT-PCR), performed utilizing a StepOne Plus real-time PCR system (Applied Biosystems, Carlsbad, CA). At analysis, a 20 ll reaction mixture was composed out of 2 lL cDNA, 2 lL forward primer (200 nM), 2 ll of reverse primer (200 nM), and 10 lL of 29 SYBR green super mix (Bio-Rad Laboratories, Hercules, CA). This reaction mixture was run at universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for 60 s) as recommended by manufacturer's instructions. Forward and reverse primer sequences for both a-SMA and b-actin (housekeeping gene) were utilized as previously validated for ECF cells 9, 26 (Table 2) .
Immunofluorescence
Cells were fixed in 4% fresh paraformaldehyde in preparation for immunofluorescence staining for a-SMA. Incubation of cells with 5% bovine serum albumin at room temperature for 30 min was performed, after which mouse monoclonal a-SMA antibody (Dako, Carpinteria, CA) at a 1:200 dilution was added to all samples for 90 min. Alexa 488 goat anti-mouse IgG secondary antibody was then added at a 1:500 dilution and incubated for 1 h. The samples were then washed with HEPES buffer, mounted with vectashield mounting media containing DAPI (Vector Laboratories, Burlingam, CA) and photographed with a Leica fluorescent microscope (Leica DM 400B) equipped with a digital camera (SpotCam RT, Sterling Heights, MI).
Statistical analysis
Data for immunohistochemistry were quantified by assessing the number of aSMA and DAPI-positive cells in 10 randomly selected nonoverlapping fields at 1009 magnification under Leica Fluorescent microscope (Leica) by evaluators masked to the treatment group (AS, RT).
Results for all values were expressed as a mean value AEstandard deviation. Statistical analysis of qRT-PCR data was performed using a one-way analysis of variance (ANOVA) followed by a Tukey's test. A value of P ≤ 0.05 was considered significant.
RE SUL TS
Effect of individual Smad gene silencing on the expression of aSMA mRNA
To investigate the effect of individual Smad gene silencing on ECF differentiation, expression of aSMA was quantified with qRT-PCR. compared to the control (4.5-5.5-fold AE0.53; P < 0.01). However, no significant differences in the inhibition of aSMA mRNA among individual Smad2, 3 and 4 groups were observed. Shows the quantification of aSMA expression demonstrating a significant increase in aSMA+ by TGF-b1 (*P < 0.01) and (**P < 0.01). The DAPI-staining (blue) depicts that there was no significant difference in the total number of nuclei between control and transfected cultures. plasmid, grown in the presence or absence of TGFb1, and expression of aSMA protein, was quantified using immunofluorescence. The knockdown of Smad2, 3 or 4 significantly attenuated TGFb1-mediated increase in aSMA (P < 0.001) ( Fig. 2; Part A) . ECFs transfected with a naked plasmid and grown in the absence of TGF-b1 demonstrated 3-5% level of aSMA+ cells (negative control; Fig. 2; Part A-a) . ECF cells transfected with a naked plasmid and grown in the presence of TGF-b1 demonstrated 95-98% level of aSMA+ cells (positive control; Fig. 2; Part A-b) . The inhibition of aSMA+ cells by Smad2 RNAi was 80% ( Fig. 2 ; Part A-c), Smad3 RNAi was 78% ( Fig. 2; Part A-d) , and Smad4 RNAi was 73% ( Fig. 2; Part A-e) . The decrease in the aSMA+ cells among the Smad2/3/4 silencing was not statistically significant ( Fig. 2 ; Part B, P = 0.8324). Due to the Smad2 RNAi having the highest inhibition of aSMA cells, this RNAi was selected for testing in combination with Smad7 overexpression for the remainder of the experiment.
Effect of individual
Comparison of single and 2-gene combination therapy on the expression of aSMA mRNA Figure 3 shows qRT-PCR quantification of single and 2-gene combination therapy on ECF differentiation. ECF cultures transfected with naked vector, Smad7 alone or Smad7 in combination with Smad2 RNAi, grown in AETGF-b1, and used for aSMA mRNA quantification are represented in Fig. 3 . Naked vector-transfected ECF cultures grown in the presence of TGF-b1 showed significantly higher levels of aSMA mRNA compared to the cultures grown in the absence of TGF-b1 (7.2-fold AE0.44; P < 0.01). Both, single (Smad7 alone) and 2-gene combination (Smad7 and Smad2 RNAi) gene transfer yielded nearly a six-fold decrease in the aSMA mRNA levels compared to naked vector-transfected cultures grown in the presence of TGF-b1 (P = 0.01). The 2-gene combination showed a slightly higher decrease in aSMA mRNA levels compared to Smad7 alone. However, this difference was not statistically significant (P = 0.369). Table 3 demonstrates the effect of Smad gene transfer on TGF-induced aSMA mRNA levels. Figure 4 shows quantification aSMA protein in ECFs transfected with naked vector, Smad7 alone, or Smad7 and Smad2 RNAi cultures grown in AETGF-b1. As expected, ECFs transfected with naked vector grown in the absence of TGF-b1 showed few aSMA+ cells (Fig. 4a) , whereas when grown in the presence of TGF-b1 demonstrated 92-96% aSMA+ cells (Fig. 4b) . Both, single (Smad7 overexpression; Fig. 4c ) and 2-gene combination (Smad2 silencing and Smad7 overexpression; Fig. 4d ) gene transfer significantly decreased ECF differentiation, exhibiting 83-85% less aSMA+ cells (P < 0.001) compared to ECFs transfected with naked vector and grown in the presence of TGF-b1. However, combination gene transfer did not have significantly lower aSMA+ cells when compared to Smad7 alone (Fig. 5 , P = 0.73).
Comparison of single and 2-gene combination therapy on the ECF differentiation
DISCUSSION
Corneal repair due to injury and/or disease is a multistep process that utilizes a variety of different cytokines and profibrotic genes to make the necessary changes within a corneal fibroblast resulting in the transdifferentiation to a myofibroblast. Transdifferentiated myofibroblasts result in a corneal opacity (scar), which results in visual defects. 10 Gene therapy is a budding field in veterinary medicine. Our group has previously reported the antifibrotic effects of a variety of different potential topical therapeutics in both equine and canine cell lines. [9] [10] [11] 13, 27 This paper differs from our previous reports as we aimed to target specific genes in the fibrotic cascade versus utilizing agents with broader spectrum antifibrotic actions.
This investigation supports the conclusion that Smad7 is the gene with the most promise for targeted antifibrotic gene therapy in equine ophthalmology. A significant decrease in the severity of fibrotic change when Smad7 is specifically expressed occurs across a variety of different species and tissues; for example, Smad7 has previously been reported to decrease corneal haze after photorefractive surgery in a rat, 28 and in the kidney, 29 liver, 30 and lungs of other animal models. 31 These findings support the idea that its role within the cytoplasm of the cell is potentially overriding the fibrotic effects of other Smad genes. Smad7 becomes activated within the cornea due to the expression of TGF-b. 28 Once activated, Smad7 blocks the TGF-b-dependent phosphorylation of Smad2 and Smad3, thereby preventing their coupling with Smad4 and subsequent translocation into the cell nucleus. 19, 32 Based on our research, this negative feedback loop, once overexpressed, can significantly reduce the severity of fibrosis in ECFs. It was noted in part (a) of this experiment that Smad2, 3, or 4 all had similar effects in the degree of aSMA reduction. While it was not surprising that inhibition of Smad2 and 3 had similar results as they both become activated in similar ways, it was interesting that inhibition of Smad4 did not have a more significant impact on the transdifferentiation of ECFs. Smad4 is considered a common-partner Smad, in that it aids in the delivery of phosphorylated Smad2 and Smad3 to the nucleus of the cell. 33 Therefore, it is reasonable to speculate that its inhibition would have caused a more significant inhibition in fibrotic change, as Smad4 could theoretically block Smad2 and Smad3 in an indirect manner. The similar response noted between all groups in this study is likely due to TGF-b1 activating Smad-independent pathways for eventual ECF transdifferentiation and thereby circumventing the Smad-dependent pathway of transdifferentiation. An alternative pathway that has been known to be activated by the TGF-b superfamily includes the p38 mitogen-activated protein kinase (MAPK) signaling pathway. 34, 35 It has been shown that blocking this pathway can also reduce the transdifferentiation of mouse mammary cells and yet has little effect on the degree to which Smad2 is phosphorylated. 36 A mouse model of renal fibrosis showed that both pathways are independent yet both play roles in the development of renal fibrosis. 37 Therefore, we believe it is highly likely that an alternative pathway became active in our study due to supplementation of TGF-b1 to our cell cultures resulting in similar ECF to ECM transdifferentiation between groups.
An unexpected result of this experiment is that no significant benefit was detected when inhibition of the profibrotic Smad2 gene was used in conjunction with overexpression of the antifibrotic Smad7 gene. A potential explanation as to why this finding occurred could be related to the fact that Smad7 prevents the TGF-bdependent phosphorylation of both Smad2 and Smad3. As this phosphorylation process is needed to activate these profibrotic Smad genes, it is likely that overexpression of the Smad7 gene in our in vitro model adversely affected this process. Therefore, the additional inhibition of the Smad2 gene in ECFs did not yield any significant antifibrotic benefit. This finding is consistent with other reports in the literature where similar results have been observed in a mouse model of myocardial fibrosis and rabbit corneal endothelial cells. 38, 39 It should be noted that our negative control group expressed SMA at a level of 3-5% in the absence of TGFb. This finding is likely related to normal culture conditions in a tissue culture plate, which can cause fibroblasts to shift from one phenotype to another spontaneously. Regardless this level of SMA expression is consistent with other scientific reports involving equine fibroblasts in an in vitro setting. 9, 11, 25 While a variety of research has been performed evaluating gene therapy utilizing Smad 7, only a few studies have evaluated corneal gene therapy with Smad7 on an in vivo model. These two studies include using a lentiviral vector with Smad7 in rats after photorefractive keratotomy 28 and a recent article from our laboratory utilizing an adenoassociated virus vector with Smad7 in a rabbit after photorefractive keratotomy. 40 The results of both of these studies indicate that Smad7 was able to reduce the severity of corneal haze compared to controls in an in vivo model. These findings are important as they further support our in vitro results.
Relatively little information is present in the veterinary literature regarding gene therapy to the equine cornea. 9, 12 To our knowledge, this is the first paper describing the effects of Smad gene expression in a large animal species. In summary, this study identifies increased Smad7 gene expression as a potential target for future ex vivo or in vivo corneal gene therapy experiments. Additionally, this paper identifies that an enhanced antifibrotic effect as determined in the degree of ECF to ECM transdifferentiation is not present when inhibition of a profibrotic Smad gene is coupled with expression of the antifibrotic Smad7 gene in an in vitro model. Future studies are needed to determine whether overexpression of Smad7 together with MAPK signaling inhibition offers improved antifibrotic activity as noted in nonocular tissues 37 than Smad therapy alone.
